NRIX — Nurix Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1549595 ·
Last close
$16.95
Market Cap
$1.75B
52W High
$18.91
52W Low
$14.01
ADV30
2,148,817
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Feb 2026 | 6,252,000 | — | -92,495,000 | -87,174,000 | 636,130,000 | 71,195,000 | 155,237,000 |
| Nov 2025 | 13,577,000 | — | -83,095,000 | -78,221,000 | 688,135,000 | 246,960,000 | 149,388,000 |
| Aug 2025 | 7,894,000 | — | -91,385,000 | -86,421,000 | 522,472,000 | 78,438,000 | 150,220,000 |
| May 2025 | 44,056,000 | — | -48,322,000 | -43,464,000 | 591,555,000 | 84,260,000 | 143,952,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-260,292,000
Investing CF
$-1,506,000
Financing CF
$257,144,000
CapEx
$-11,562,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.16
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,090,400,000
Inventory
—
Receivables
$19,000,000
ST Investments
$469,537,000
EBIT TTM
$-315,297,000
Pretax Income TTM
$-294,520,000
Interest Exp TTM
—
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,779,000
EBITDA
$-307,311,008
Free Cash Flow
$-145,462,624
Enterprise Value
$1,270,651,520
Total Cash
$540,732,032
Total Debt
$58,655,000
Shares Out
103,405,813
Trailing EPS
$-3.17
Book Value
$4.65
ROE
-61.4%
ROA
-31.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 83,980,000 | -285,666,000 | -264,457,000 | 688,135,000 | 149,388,000 | — | -249,465,000 |
| Nov 2024 | 54,549,000 | -213,027,000 | -193,569,000 | 669,343,000 | 142,350,000 | — | -172,584,000 |
| Nov 2023 | 76,987,000 | -155,063,000 | -143,948,000 | 355,598,000 | 155,105,000 | — | -81,365,000 |
| Nov 2022 | 38,627,000 | -183,867,000 | -180,360,000 | 416,759,000 | 113,063,000 | — | -159,807,000 |
TTM Snapshot
Revenues TTM
$41,846,000
NetIncome TTM
$-131,647,000
OpCashFlow TTM
$0
Assets (Latest)
$669,343,000
Forward EPS
$-2.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.75B | $29.46 | — |
| QURE | uniQure N.V. | $1.74B | $27.57 | — |
| NUVB | Nuvation Bio Inc. | $1.71B | $4.92 | — |
| NBTX | Nanobiotix S.A. | $1.80B | $35.54 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $1.81B | $16.35 | — |
News headlines (Yahoo Finance, 1h cache)
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
2026-06-15 12:20 · Yahoo
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
2026-06-11 11:00 · Yahoo
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
2026-06-11 09:12 · Yahoo
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
2026-06-09 10:21 · Yahoo
Company News for Jun 9, 2026
2026-06-09 08:27 · Yahoo
Broader Market Settles Higher as Chipmakers Rally
2026-06-08 20:33 · Yahoo
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
2026-06-08 20:03 · Yahoo
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
2026-06-08 19:35 · Yahoo
Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion
2026-06-08 15:44 · Yahoo
Stocks Rally as Buyers Return After AI-Led Selloff
2026-06-08 15:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.